NCT02105311View on ClinicalTrials.gov

Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Intraocular Pressure
Interventions
DEVICE

Selective laser trabeculoplasty

Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)

DRUG

Travoprost

Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)

Trial Locations (1)

90110

Songklanagarind Hospital, Hat Yai

All Listed Sponsors
lead

Prince of Songkla University

OTHER

NCT02105311 - Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure | Biotech Hunter | Biotech Hunter